Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple light be the answer to itching?

NCT ID NCT07450716

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive near-infrared LED light device can safely relieve itch. Twenty adults with acute or chronic itch will receive light treatments, and researchers will measure changes in itch intensity using a standard rating scale. The goal is to see if this gentle light therapy can reduce itch without side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant is an adult at least 18 years-of-age. 2. Participant meets the criteria for acute or chronic itch as defined below: 1. Acute itch lasting less than 6 weeks. 2. Chronic itch lasting more than 6 weeks. 3. Participant is able and willing to comply with all the study visit, treatment, and evaluation schedules and requirements. 4. Participant can understand and provide written informed consent. 5. Participant does not have any concurrent injury or wound in their target treatment area. 6. Participant is either untreated for their pruritus, or if on therapy, must have been maintained on a stable regimen of antipruritic treatments for the past 14 days prior to enrollment. 7. Participant has mild, moderate, or severe pruritus as defined below: 1. Mild: average score \<4 on the PP-NRS during the week before baseline. 2. Moderate: average score 4-7 on the PP-NRS during the week before baseline. 3. Severe: average score of \> 7 on the PP-NRS during the week before baseline. 8. Participants must have comparable pruritus affecting symmetrical or corresponding areas on both sides of their body to allow for the split-body study design. Exclusion Criteria: 1. Participant has any active internal or cutaneous malignancy located within the proposed treatment area. 2. Participant cannot provide informed consent or adhere to study schedule. 3. Participant is actively tanning during the study course. 4. Participant has melasma or another condition exacerbated by heat. 5. Participant is on a photosensitizing medication, such as doxycycline or has a photosensitizing condition. 6. Patient is currently pregnant or breastfeeding. 7. Participant has psychogenic pruritus, a diagnosed skin-picking (excoriation) disorder, or any other current psychiatric condition that, in the investigator's judgment, could interfere with informed consent, adherence to the study protocol, or safe participation. 8. Participant has any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pruritus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Wellman Center for Photomedicine, Massachusetts General Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.